Physician profile
John Bianco
NPI 1669092144
$4,272.24
in general payments reported to CMS, 2019-2025
26 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $54.84 · 2023: $589 · 2024: $2,143 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,217.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,712.55 | 2023-2025 | Vraylar, Qulipta, Viberzi |
| Lilly USA, LLC | $482.28 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $459.62 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $374.29 | 2023-2025 | |
| Amgen INC. | $174.83 | 2023-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $172.51 | 2024-2025 | Airsupra, Farxiga, Fasenra |
| Glaxosmithkline, LLC. | $143.89 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.67 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $71.54 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.73 | 2023-2024 | Xifaxan, Trulance |
| Ardelyx, INC. | $66.13 | 2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $56.08 | 2023-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $50.46 | 2024 | |
| Phathom Pharmaceuticals, INC. | $48.64 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $48.55 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $44.78 | 2024-2025 | Nexletol |
| Organon LLC | $37.34 | 2022 | |
| Halozyme INC | $24.15 | 2023 | |
| Corium, LLC | $23.25 | 2024 | Azstarys |
| Lundbeck LLC | $22.64 | 2024 | Vyepti |
| Astellas Pharma US INC | $22.22 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $20.08 | 2025 | Trintellix |
| Antares Pharma, INC. | $18.36 | 2024 | Xyosted |
| Baxter Healthcare | $17.50 | 2022 | |
| Exact Sciences Corporation | $14.72 | 2025 | Cologuard Collection Kit |
| Noven Therapeutics, LLC | $14.43 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bianco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.